Does Wegovy Affect Liver Function — and What Does the Evidence Say?

What clinical trials found about semaglutide and liver fat

The evidence base here is more encouraging than many people expect. In the STEP 1 trial, published in the New England Journal of Medicine, participants taking semaglutide 2.4mg lost an average of around 15% of body weight over 68 weeks. A consistent finding across the wider semaglutide programme is that significant weight loss tends to reduce liver fat, a biologically logical relationship, because excess fat stored in the liver (hepatic steatosis) is closely tied to overall adiposity and metabolic health.

Beyond weight loss alone, dedicated trials have examined semaglutide's effect on MASH, metabolic dysfunction-associated steatohepatitis, a more advanced form of fatty liver disease involving inflammation and potential scarring. The results were striking enough that, on 3 July 2026, the MHRA granted conditional approval for Wegovy specifically to treat MASH in adults with moderate-to-advanced fibrosis. That made Wegovy the first GLP-1 receptor agonist to receive this indication in the UK, a meaningful regulatory milestone, and a signal that the safety profile in people with liver disease was judged acceptable by regulators.

If you are wondering whether these changes show up in routine blood tests, our page on whether Wegovy affects liver enzymes looks at what the evidence says about ALT, AST and related markers. This improvement tracks weight reduction rather than being a direct pharmacological effect on the liver.

Does Wegovy raise liver enzymes or cause liver damage?

A question our prescribers hear most weeks is whether starting Wegovy might make liver blood tests worse. The current evidence does not suggest this for the majority of people. There is no established signal in trial data or regulatory guidance indicating that semaglutide causes direct liver toxicity in adults without pre-existing serious liver conditions.

That said, the picture is not unconditionally clean. Severe gastrointestinal side effects (persistent vomiting or diarrhoea) can occasionally lead to dehydration, which may place secondary strain on multiple organs including the kidneys and liver. If you develop significant GI symptoms that are not settling, that is a reason to contact your prescriber or GP rather than waiting.

People with severe hepatic impairment were not well represented in the pivotal trials, so prescribers are appropriately cautious in that group. If you have a known liver condition, the prescriber's assessment at consultation will take that into account. Our dedicated page on whether Wegovy can affect your liver is worth reading if your GP monitors your LFTs regularly. The NHS medicines page on semaglutide also lists the full side-effect profile reviewed by the MHRA.

The pancreatitis caution, and why it matters here

One safety communication that bears on liver-adjacent symptoms is the MHRA's Drug Safety Update from January 2026, which highlighted acute pancreatitis as an infrequent but potentially serious side effect of GLP-1 medicines including semaglutide. The reason this matters in a liver-function context is that pancreatic and liver pain can feel similar: both can cause upper abdominal discomfort, sometimes radiating to the back, sometimes with nausea.

If you develop severe, persistent stomach pain (particularly if it spreads toward your back and is accompanied by vomiting) seek urgent medical help and tell the treating clinician you take semaglutide. Do not self-manage and wait. The MHRA Yellow Card scheme is also available if you experience unexpected effects and want to report them directly.

Gallbladder problems are a separate but related concern: rapid weight loss of any kind can increase the risk of gallstones, and GLP-1 treatment is no different. Right-sided upper abdominal pain, particularly after eating, should be discussed with a GP promptly. These are different from pancreatitis symptoms but worth knowing.

Who should discuss liver health with a prescriber before starting

For most adults who meet the licensed eligibility criteria (BMI of 30 or above, or 27 or above with a weight-related condition) there is no specific liver contraindication that rules out Wegovy. The MASH approval actually extends access to a group with significant liver disease who previously had limited pharmacological options.

Those who should specifically raise liver health at consultation include anyone with a history of hepatitis, cirrhosis, alcohol-related liver disease, or abnormal liver function tests flagged by their GP. How semaglutide interacts with pre-existing liver conditions is covered in more depth for those situations. If you are weighing up the evidence and want a fuller picture, our page on whether Wegovy can affect your liver walks through the key considerations in plain language. Pregnancy and breastfeeding are separate contraindications: Wegovy is not recommended during pregnancy, while breastfeeding, or if you are trying to conceive, regardless of liver status, discuss with your doctor if any of these apply. Under-18s are not a licensed population.

If you're ready to talk through your own circumstances, starting a free consultation puts your answers in front of a GPhC-registered prescriber the same day, a real clinician reviews every case personally before any treatment is considered. You can also read more about how Wegovy works or explore the broader picture on our weight-loss treatments overview.